News :
Impact of Hyperthermia on Quality of Life (QoL): Pain Relief, Fatigue Reduction, and Adjuvant Immunological Benefits Hyperthermia and Survival of Cancer Patients: Clinical Evidence Demonstrating an Increase in Overall Survival (OS) by Over 50% Therapeutic Integration of Hyperthermia in Modern Oncology: A Critical Analysis of Phase III Trials and Meta-Analyses (OS, DFS, CR Endpoints) Quasi feasibility study(case control) associating deep local hyperthermia treatment with standard cancer treatments and describing patterns of response ESHO Preliminary results of chemoradiation plus hyperthermia and high dose rate brachytherapy for locally advanced cervical carcinoma ESHO

European Society for Hyperthermic Oncology Congress

ESHO 2024 Málaga | Advanced Oncologic Hyperthermia

ESHO 2024 Malaga Spain Conference

ESHO 2024 – Málaga, Spain: Presenting the future of Thermotherapy.

Andromedic – advanced oncological hyperthermia systems producer participated at

36th Annual Meeting of the European Society for Hyperthermic Oncology (ESHO 2024)

Abstract Presented by SIIO

Italian Society of Oncological Hyperthermia (Società Italiana di Ipertermia Oncologica – SIIO): Foundation, activities and future projects to develop thermotherapy and hyperthermia in Italy

Authors: G. Fiorentini1, G. Ranieri2, M. Bonucci3, S. Bonanno4, G. Cristina5, R. Lodico6, D. Sarti7

  1. San Salvatore Hospital, Oncology, Pesaro, Italy
  2. National Cancer Institute, Oncology, Bari, Italy
  3. ARTOI Foundation, Integrative Oncology, Roma, Italy
  4. Regional Hospital, Radiotherapy, Siracusa, Italy
  5. Regional Hospital, Internal Medicine – Complementary Medicine, Merano, Italy
  6. San Camillo Forlanini, Surgical Oncology, Roma, Italy
  7. Oncology Unit, Urbino, Italy

The Italian Society of Oncological Hyperthermia (SIIO) was founded in September 2023 to promote oncological hyperthermia in Italy and develop it on the national territory to better serve cancer patients (CP).

Methods

SIIO is recruiting up to now 20 centres including public hospitals and private clinics. All hyperthermia centres have adhered to the proposed statute and code of ethics of SIIO. The following themes were approved and proposed:

  • To promote dissemination of knowledge in Thermotherapy and related fields through publications, meetings and educational symposia.
  • To encourage the advancement of Hyperthermia in all areas of medical sciences.
  • To facilitate cooperative research among the disciplines of physics, engineering, biology, chemistry, and medicine in the study of the properties and effects of Hyperthermia in Medicine including limb and visceral hyperthermic perfusions, Laser treatments and Radiofrequency ablations.
  • To organize a national database regarding tumours treated with hyperthermia: type, stage, line of therapy, therapeutic results, toxicities and survival.
  • To define new integrated protocols (Phase II and III) of chemo-hyperthermia, radio-hyperthermia, immuno-hyperthermia, and palliative medicine-hyperthermia.

Results

The collections of the preliminary data obtained are being processed. Approximately three thousand patients are treated with hyperthermia every year in Italy (86% in private clinics, 14% in public hospitals), all in the metastatic phase relapsing after chemotherapy and radiotherapy with a life expectancy ranging from 3 to 24 months.

Each patient received an average of eleven hyperthermia sessions (range 3-28) utilizing different types of hyperthermia devices: Andromedic, Oncotherm, BSD, Celsius, Syncrotherm. The duration of treatment was 55 minutes, with 2-3 weekly sessions. 50% of CP received single chemotherapy at personalized doses and 90% received integrative and supportive therapies. Particular attention was given to evaluating the improvement in patients’ quality of life using the ESAS scale.

Conclusions

SIIO aims to expand the therapeutic paradigm through the numerical increase of hyperthermia centres and the training of expert doctors, technicians, and nurses. SIIO intends to collaborate with the Italian Ministry of Health and medical associations to provide truthful information and optimize costs, facilitating patient access to hyperthermic treatments across National Territory and European Nations.

SRHO: A Shared European Mission for Social Impact

Aligned with the mission of SIIO in Italy, the Romanian Society of Oncological Hyperthermia (SRHO) operates as a unique hybrid entity, serving as both a Scientific Society and a certified Social Enterprise.

In strict compliance with its Constitutive Act and Romanian social economy legislation, SRHO is dedicated to democratizing access to advanced hyperthermia treatments. As a non-profit organization focused on the public good, SRHO reinvests at least 90% of its generated surplus back into its core social and scientific missions:

  • Patient Support: Providing direct financial assistance and counseling for cancer patients to access life-extending treatments.
  • Scientific Advancement: Standardizing clinical protocols in Romania based on ESHO/DGHT international benchmarks.
  • National Integration: Collaborating with the Romanian Ministry of Health to include hyperthermia in national treatment protocols and optimize costs for equitable access.

“Our goal is to ensure that oncological hyperthermia—a clinically validated therapy—becomes a widely accessible reality for all Romanian patients, independent of their socio-economic status”.